Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04433585 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 291
- Enrollment target
NCT04433585 is a Phase 2 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 291 participants.
The verdict
NCT04433585, a Phase 2 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 291 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG LY3471851
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2023-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04433585
The ClinicalTrials.gov registry entry for NCT04433585 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04433585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04433585 about?
NCT04433585 is a clinical study titled "A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)". The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
What is the current status of trial NCT04433585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 291 participants. The study started on 2020-08-19. Estimated completion is 2023-02-16.
What interventions are being tested in trial NCT04433585?
The interventions under investigation include: Placebo (DRUG), LY3471851 (DRUG).
Who is sponsoring clinical trial NCT04433585?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.